Zakharov V.V. 1*, Tkacheva O.N. 2*, 3*, Mkhitaryan E.A. 2*, 3*, Fedin A.I. 2*
1* I.M. Sechenov First Moscow State Medical University of the Russian Ministry of Healthcare
(Sechenov University), Moscow, Russia;
2* N.I. Pirogov Russian National Research Medical University of the Russian Ministry of Healthcare,
Moscow, Russia;
3* Russian Gerontology Research and Clinical Center of N.I. Pirogov Russian National Research
Medical University of the Russian Ministry of Healthcare, Moscow, Russia
Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry
2022, Vol. 122, No. 11, Issue 2, pp. 73–80
Abstract
Objective. To evaluate the efficacy of sequential therapy with Mexidol and Mexidol FORTE 250 compared with placebo in patients with chronic cerebral ischemia (CCI) of different age subgroups. Material and methods. A subanalysis of data from the international multicenter, randomized, double-blind, placebo-controlled MEMO study is presented. The study included 318 patients (25% men) aged 40 to 90 (median 60) years. Treatment efficacy was assessed in three age groups: 40–60 (n=163), 61–75 (n=141), and 76–90 (n=13) years. The primary efficacy endpoint was the dynamic increase in the MoCA score as the absolute difference between the score before treatment and on day 75 of therapy. The dynamics of the total scores for the following questionnaires and scales were considered as secondary efficacy endpoints: the digital symbol substitution test, the SF-36 quality of life questionnaire, the MFI-20 subjective asthenia assessment scale, the Wein autonomic disturbance questionnaire, the Beck anxiety scale, and the Tinetti motor activity scale.
Results.
The positive dynamics of the severity of cognitive, emotional and motor disorders in groups 40-60 and 61–75 years after 75 days of therapy was detected in patients who received both Mexidol and placebo, however, in patients receiving Mexidol, these changes turned out to be more pronounced, which indicate the higher values of the absolute difference in the amount of the points of the studied indicators.
Conclusion.
The study results showed that patients with chronic cerebral ischemic attack (CCI) experienced significantly greater improvements in cognitive and motor function, improved quality of life, and reduced severity of autonomic dysfunction, asthenia,
and anxiety after 75 days of treatment with Mexidol compared to placebo. These
results support the use of Mexidol in the treatment of patients of all ages with CCI.
Key words:
Cognitive disorders, chronic brain ischemia, Mexidol, Mexidol Fort 250, ethylmethylhydroxypyridine succinate, examination of memes.
